Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340306 | 0.84 | ATR (0.36) | SYKCYP2D6TSHR | |
| SCHEMBL1368571 | 0.84 | ERCC1 (0.47) | SYKCYP2D6JAK3JAK2JAK1 | |
| SCHEMBL1896593 | 0.81 | JAK3 (0.49) | SYKCYP2D6JAK3 | |
| SCHEMBL1370960 | 0.80 | JAK2 (0.60) | SYKJAK3JAK2JAK1 | |
| SCHEMBL1368569 | 0.79 | JAK3 (0.57) | SYKJAK3JAK2JAK1 | |
| SCHEMBL1368796 | 0.79 | JAK3 (0.61) | SYKCYP2D6JAK3JAK2JAK1 | |
| SCHEMBL1368698 | 0.79 | JAK3 (0.61) | SYKCYP2D6JAK3JAK2JAK1 | |
| SCHEMBL3395862 | 0.79 | KDM4E (0.48) | JAK3JAK2JAK1 | |
| SCHEMBL1369910 | 0.78 | JAK3 (0.46) | SYKCYP2D6JAK3JAK2JAK1 | |
| SCHEMBL1369236 | 0.77 | SYK (0.44) | SYKCYP2D6JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | claimed |
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | claimed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | claimed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2009106442-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | SYK 1/4885CYP2D6 2873/4885TSHR 1271/4885 |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | SYK 1/4885CYP2D6 2587/4885TSHR 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.